Research programme: eye disorders therapy - IOMED/SantenAlternative Names: Eye disorders therapy research programme - IOMED/Santen
Latest Information Update: 15 Feb 2002
At a glance
- Originator IOMED
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 15 Feb 2002 Discontinued-Preclinical for Eye disorders in USA (Intraocular)
- 20 Jul 2001 Preclinical development for Eye disorders in USA (Intraocular)